ABIONYX Pharma (EPA: ABNX) revenue
ABIONYX Pharma reported revenue of €4.1m for fiscal 2025, 10.7% less than in fiscal 2024 (€4.6m).
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | €4.1m | −10.7% | −€5.5m | −136.3% |
| 2024 | €4.6m | −1.9% | −€4.5m | −98.1% |
| 2023 | €4.6m | −11.7% | −€3.4m | −73.5% |
| 2022 | €5.3m | +678.1% | −€4.1m | −78.2% |
| 2021 | €0.7m | — | −€6.0m | −881.8% |
| 2020 | €0.0m | — | −€3.0m | — |
| 2019 | €0.0m | — | −€2.5m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the revenue of ABIONYX Pharma
- How much revenue did ABIONYX Pharma make in fiscal 2025?
- ABIONYX Pharma reported revenue of €4.1m for fiscal 2025, compared with €4.6m in fiscal 2024.
- What was the best year for revenue at ABIONYX Pharma?
- Of its last 7 fiscal years, fiscal 2022, with €5.3m.
- Where do the figures for ABIONYX Pharma come from?
- From the report ABIONYX Pharma files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report ABIONYX Pharma files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2023 · 2022 · 2021 · 2020. More on ABIONYX Pharma: the ABIONYX Pharma page · annual accounts · net income.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.